跳至主要内容
临床试验/NCT02144948
NCT02144948已完成3 期

Pilot Study to Investigate the Effect of E-coli-nissle as Probiotic Adjuvant to Antidiabetic Standard Care in Patients With Diabetes Mellitus Type II

GWT-TUD GmbH1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
GWT-TUD GmbH
入组人数
10
试验地点
1
主要终点
Decrease in HbA1c levels

研究概览

简要总结

This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type II

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diabetes mellitus type 2;
  • HbA1c >7 % (stable für 6 months, max. variation of 0,5%)
  • stable oral antidiabetic therapy for 6 months with Metformin, Vildagliptin, Gliniden or without oral Antidiabetics
  • age of 45 to <80 years (men and women)

排除标准

  • Myocardial infarction or stroke within the last 5 years
  • Therapy with acarbose
  • Acute peripheral arterial disease within the last 12 months
  • Instable metabolic situation
  • Uncontrolled hypertension
  • Body-Mass-Index ≥ 35 kg/m²
  • Daily consumption of probiotic food
  • Malignant disease within the last 5 years
  • Status post transplantation
  • Immunosuppressive therapy within the last 3 months
  • Therapy with antibiotics
  • Macroalbuminuria
  • Severe liver disease

研究组 & 干预措施

E.-coli-Nissle

Experimental

10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd

干预措施: e.-coli-nissle (Drug)

结局指标

主要结局

Decrease in HbA1c levels

时间窗: 24 weeks

次要结局

  • change in insulin resistance/secretion(24 weeks)
  • change in parameters of oxidative stress(24 weeks)
  • change in lipid parameters(24 weeks)
  • change in gastrointestinal condition(24 weeks)

研究者

发起方
GWT-TUD GmbH
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验